Trial reportJournal of the American College of Cardiology2020
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque.
Trial report in Journal of the American College of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-center, Randomized, Parallel-group, Open-label Pilot Study to Evaluate the Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
A Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients With ACS- PROSPECT II (Natural History Study), Combined With a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)
Intracoronary Cryotherapy Effect for staBilization of vulnErable Plaque at Risk of Rupture as Assessed by imaGing
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Randomized Trial
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Preventive percutaneous coronary intervention versus optimal medical therapy for vulnerable plaque: a meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Outcomes of deferred revascularisation following negative fractional flow reserve in diabetic and non-diabetic patients: a meta-analysis.Cardiovascular diabetology · 2023Pooled it
- Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Trial
- Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheroma.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Trial
- Clinical outcomes of no stenting in patients with ST-segment elevation myocardial infarction undergoing deferred primary percutaneous coronary intervention.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022Trial
- Reduction of Lipid-Core Burden Index in Nonculprit Lesions at Follow-Up after ST-Elevation Myocardial Infarction: A Randomized Study of Bioresorbable Vascular Scaffold versus Optimal Medical Therapy.Journal of interventional cardiology · 2021Trial
- Optimal revascularization strategy in patients with acute coronary syndrome and multivessel disease: insights from a network meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Impact of Diabetes on Coronary Plaque Stabilization With Evolocumab: Insights From the YELLOW III Trial.Cardiovascular drugs and therapy · 2026Article
- Long-term outcomes after resting full-cycle ratio and deferral of revascularization.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Article
- From Plaque to Perfusion: A Narrative Review of Multimodality Imaging in Acute Coronary Syndromes.Journal of clinical medicine · 2026Article
- Can calcified plaque guide effective revascularization strategies?American journal of preventive cardiology · 2026Article
- The Role of GH-IGF-1 Axis and S-Klotho in Atherosclerosis Natural History, Plaque Phenotype and Vulnerability: A Narrative Review.Biomedicines · 2026Review
- Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Intracoronary Imaging for the Management of Vulnerable Plaques.Journal of clinical medicine · 2026Review
- Stepwise Assessment of Computational Coronary Physiology and Plaque Vulnerability: Impact on Coronary Revascularization Decision Making.JACC. Asia · 2026Article
- Efficacy of intravascular ultrasound-guided primary percutaneous coronary intervention in acute coronary syndrome: a meta-analysis of randomized controlled trials with meta-regression.Annals of medicine and surgery (2012) · 2026Article
- A CCTA coronary plaque radiomic model for predicting major adverse cardiovascular events in patients with coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
- Impact of low-density lipoprotein cholesterol-lowering therapy on intermediate stenosis in non-culprit vessels of acute coronary syndrome.BMC cardiovascular disorders · 2025Article
- Prognostic Role and Therapeutic Implications of Intravascular Optical Coherence Tomography Detected Coronary Plaque Microstructures in Patients with Coronary Artery Disease.Journal of clinical medicine · 2025Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 13 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute coronary syndromes most commonly arise from thrombosis of lipid-rich coronary atheromas that have large plaque burden despite angiographically appearing mild.
objectivesThis study sought to examine the outcomes of percutaneous coronary intervention (PCI) of non-flow-limiting vulnerable plaques.
methodsThree-vessel imaging was performed with a combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) catheter after successful PCI of all flow-limiting coronary lesions in 898 patients presenting with myocardial infarction (MI). Patients with an angiographically nonobstructive stenosis not intended for PCI but with IVUS plaque burden of ≥65% were randomized to treatment of the lesion with a bioresorbable vascular scaffold (BVS) plus guideline-directed medical therapy (GDMT) versus GDMT alone. The primary powered effectiveness endpoint was the IVUS-derived minimum lumen area (MLA) at protocol-driven 25-month follow-up. The primary (nonpowered) safety endpoint was randomized target lesion failure (cardiac death, target vessel-related MI, or clinically driven target lesion revascularization) at 24 months. The secondary (nonpowered) clinical effectiveness endpoint was randomized lesion-related major adverse cardiac events (cardiac death, MI, unstable angina, or progressive angina) at latest follow-up.
resultsA total of 182 patients were randomized (93 BVS, 89 GDMT alone) at 15 centers. The median angiographic diameter stenosis of the randomized lesions was 41.6%; by near-infrared spectroscopy-IVUS, the median plaque burden was 73.7%, the median MLA was 2.9 mm
conclusionsPCI of angiographically mild lesions with large plaque burden was safe, substantially enlarged the follow-up MLA, and was associated with favorable long-term clinical outcomes, warranting the performance of an adequately powered randomized trial. (PROSPECT ABSORB [Providing Regional Observations to Study Predictors of Events in the Coronary Tree II Combined with a Randomized, Controlled, Intervention Trial]; NCT02171065).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.